Michael D. Casey Joins Schein Pharmaceutical As Executive Vice President.

Casey, former president and chief operating officer of Genetic Therapy Inc. (GTI), has joined Schein Pharmaceutical Inc. as executive vice president, the company announced today.

Casey was recently responsible for driving GTI's rapid growth and positioning the company for a successful sale to Sandoz Pharmaceuticals. He will now play a key role in the overall management of Schein.

Among other responsibilities, Casey will lead Schein's Business Development function and serve as a member of the company's Office of the Chairman, an executive management group. Casey will report directly to Martin Sperber, chairman and chief executive officer.

Casey possesses broad experience in the areas of sales and marketing, business development, licensing and general management, attained through a notable career within the Johnson & Johnson (J&J) organization. Prior to GTI, Casey was president of McNeil Pharmaceutical, responsible for the successful launch of Floxin which marked J&J's entry into the competitive antibiotic category.

Previously, during his 25-year tenure at J&J, Casey held positions of increasing responsibility, beginning as a Field Sales representative in 1968 and rising to vice president, Sales and Marketing for Ortho Pharmaceutical. For the past four years, Casey has served on the Associate Member Board of the Executive Committee of the National Wholesale Druggists' Association

"I am extremely excited that Mike Casey is joining the Schein senior management team," said Martin Sperber, chairman and chief executive officer. "He brings a record of accomplishments in the pharmaceutical industry and a wealth of management experience and insight which will further strengthen the company's leadership.'

Schein Pharmaceutical Inc. is one of the largest and most diversified multisource pharmaceutical companies in the United States, manufacturing over 400 products in nearly every therapeutic category. The company maintains high-quality manufacturing facilities, invests significantly in product development and focuses on controlling healthcare costs through state-of-the art production, distribution and competitive pricing of quality medication.

In September, Schein acquired Marsam Pharmaceuticals -- the only domestic multisource injectable firm with the ability to manufacture any type of injectable drug, including penicillins, cephalosporins and non-antibiotics -- which greatly expanded the company's product portfolio.

Schein employs approximately 1800 people at facilities in Florham Park, N.J., Carmel, N.Y., Brewster, N.Y., Cherry Hill, N.J., Danbury, Conn., Phoenix, Ariz. and Humacao, Puerto Rico.

CONTACT: Suzanne Soderberg,

201/593-5565 (phone), 201/593-5820 (fax)